In an observational study, antihypertensive treatment was not associated with reduced mortality or rates of CVD in low-risk patients with mild hypertension.
The ODYSSEY OUTCOMES trial met its primary safety endpoint, showing reduced risk of MACE with alirocumab in patients with ACS compared to placebo, which is dependent on baseline LDL-c levels.
In a large cohort study, pulse pressure stress index (P2SI) was inversely associated with risk of HF and all-cause mortality in individuals with suspected CAD.
A retrospective study showed that a high percentage of patients undergoing PCI have persistent high residual inflammatory risk, which results in a higher one year rate of all-cause death and myocardial infarction.
In a substudy of GLAGOV, IVUS-based virtual histology showed regression of coronary atherosclerosis in evolocumab-treated patients, but no changes in plaque composition as compared with placebo.
In patients with an established diagnosis of hypercholesterolemia, tocilizumab blunted the NSTEMI-associated PCSK9 increase and this was strongly correlated with a decrease in neutrophil numbers.
ESC 2018 Results of the VERDICT trial were neutral for an early intervention strategy compared to standard management in NSTEMI patients. However, a beneficial effect of early intervention was observed in those with a GRACE score >140.
ESC 2018 Only some high-risk patients may benefit from very early (<12 hours) coronary angiography plus PCI or CABG when NSTEMI ACS is suspected.
ESC 2018 Prof. Serruys gives a brief overview of the study design and results of the GLOBAL LEADERS trial in patients post-ACS and with stable angina.
ADA 2018 Analysis of ODYSSEY OUTCOMES trial indicates people with diabetes and prior ACS benefit most from the combination of alirocumab and statins, compared to ACS survivors with prediabetes or with normal glucose levels
Patients with a transient ischemic attack or minor stroke had a sustained elevated risk of CV events up to 5 years after the first event, and approximately half of these events occurred after the first year.
ACC 2018 Results of the SECURE-PCI trial showed a 28% decrease of MACE in patients treated with avorstatin compared to placebo before PCI intervention after ACS.